Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.
[INTRODUCTION] In this study, we aimed to identify biomarkers for predicting treatment outcomes and efficacy of chemotherapy plus nivolumab, as well as predict immune-related adverse events (irAEs) ch
- p-value p = 0.018
APA
Nakazawa N, Sohda M, et al. (2025). Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.. Oncology, 103(3), 201-208. https://doi.org/10.1159/000540841
MLA
Nakazawa N, et al.. "Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.." Oncology, vol. 103, no. 3, 2025, pp. 201-208.
PMID
39265540
Abstract
[INTRODUCTION] In this study, we aimed to identify biomarkers for predicting treatment outcomes and efficacy of chemotherapy plus nivolumab, as well as predict immune-related adverse events (irAEs) characteristics of immune checkpoint inhibitors.
[METHODS] This multicenter study included 104 patients who received chemotherapy plus nivolumab as the primary treatment for unresectable advanced recurrent gastric cancer. Blood test results were collected before the start and after two courses of treatment. The neutrophil-lymphocyte ratio, prognostic nutritional index, and lactate dehydrogenase/albumin ratio (LAR) were examined after treatment in each case to determine changes compared to values before the start of treatment.
[RESULTS] A total of 57 (54.8%) patients experienced a complete or partial response. The LAR of the stable disease/progressive disease group significantly increased (p = 0.018). An examination of the presence of grade ≥3 irAEs and changes in related factors showed that the LAR of all patients increased.
[CONCLUSION] The LAR was correlated with the best therapeutic response; therefore, it may be a potential biomarker of treatment outcomes and efficacy.
[METHODS] This multicenter study included 104 patients who received chemotherapy plus nivolumab as the primary treatment for unresectable advanced recurrent gastric cancer. Blood test results were collected before the start and after two courses of treatment. The neutrophil-lymphocyte ratio, prognostic nutritional index, and lactate dehydrogenase/albumin ratio (LAR) were examined after treatment in each case to determine changes compared to values before the start of treatment.
[RESULTS] A total of 57 (54.8%) patients experienced a complete or partial response. The LAR of the stable disease/progressive disease group significantly increased (p = 0.018). An examination of the presence of grade ≥3 irAEs and changes in related factors showed that the LAR of all patients increased.
[CONCLUSION] The LAR was correlated with the best therapeutic response; therefore, it may be a potential biomarker of treatment outcomes and efficacy.
MeSH Terms
Humans; Stomach Neoplasms; Male; Female; Nivolumab; Middle Aged; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Neoplasm Recurrence, Local; Treatment Outcome; Adult; Aged, 80 and over; L-Lactate Dehydrogenase; Prognosis
같은 제1저자의 인용 많은 논문 (5)
- Real-world survival benefit of chemotherapy in elderly patients with advanced gastric cancer: a population-based SEER analysis.
- Minimally invasive versus open completion total gastrectomy for remnant gastric cancer: a nationwide propensity score-matched analysis.
- Comprehensive genetic analysis of poorly differentiated gastric cancer in young females.
- Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study.
- ASO Author Reflections: The Gustave Roussy Immune Score May Be a Useful Biomarker for Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Gastric Cancer.